Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce•
Hisse Senedi Orta Önem
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.46 per share a year ago.
İlgili Semboller 1
VNDA VNDA
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
0 0 0
Yorum Yap
Yorumlar
0
Henüz yorum yok
Bu habere ilk yorum yapan kişi olun.